Capturing B type acute lymphoblastic leukemia cells using two types of antibodies

Creative Commons License

İÇÖZ K., Gercek T., Murat A., ÖZCAN S., ÜNAL E.

BIOTECHNOLOGY PROGRESS, vol.35, no.1, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1002/btpr.2737
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: B type acute lymphoblastic leukemia cells, cell capture efficiency, minimal residual disease, immunomagnetic separation, two antibody sorting, MINIMAL RESIDUAL DISEASE, IMMUNOMAGNETIC SEPARATION, PERIPHERAL-BLOOD, CANCER-CELLS, TUMOR-CELLS, IN-VITRO, AMPLIFICATION, SALMONELLA, PARTICLES, BACTERIA
  • Abdullah Gül University Affiliated: Yes


One way to monitor minimal residual disease (MRD) is to screen cells for multiple surface markers using flow cytometry. In order to develop an alternative microfluidic based method, isolation of B type acute lymphoblastic cells using two types of antibodies should be investigated. The immunomagnetic beads coated with various antibodies are used to capture the B type acute lymphoblastic cells. Single beads, two types of beads and surface immobilized antibody were used to measure the capture efficiency. Both micro and nanosize immunomagnetic beads can be used to capture B type acute lymphoblastic cells with a minimum efficiency of 94% and maximum efficiency of 98%. Development of a microfluidic based biochip incorporating immunomagnetic beads and surface immobilized antibodies for monitoring MRD can be an alternative to current cost and time inefficient laboratory methods. (c) 2018 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2737, 2019